Expert consensus on maintenance treatment for metastatic colorectal cancer in China

被引：14

作者：

Xu, Rui-Hua ^{[1
,2
]}

Shen, Lin ^{[3
]}

Li, Jin ^{[4
]}

Xu, Jian-Ming ^{[5
]}

Bi, Feng ^{[6
]}

Ba, Yi ^{[7
]}

Bai, Li ^{[8
]}

Shu, Yong-Qian ^{[9
]}

Liu, Tian-Shu ^{[10
]}

Li, Yu-Hong ^{[1
,2
]}

Bai, Chun-Mei ^{[11
]}

Yuan, Xiang-Lin ^{[12
]}

Zhang, Jun ^{[13
]}

Chen, Gong ^{[1
,14
]}

Zhou, Ai-Ping ^{[15
]}

Yuan, Ying ^{[16
]}

Wang, Xi-Jing ^{[17
]}

Qian, Xiao-Ping ^{[18
]}

Deng, Yan-Hong ^{[19
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China

[3] Peking Univ, Dept Gastrointestinal Med Oncol, Canc Hosp, Beijing 100142, Peoples R China

[4] Tongji Univ, Dept Oncol, Tianyou Hosp, Shanghai 200331, Peoples R China

[5] Chinese Peoples Liberat Army, 307th Hosp, Dept Med Oncol, Beijing 100071, Peoples R China

[6] Sichuan Univ, Dept Med Oncol, West China Hosp, Chengdu 610041, Sichuan, Peoples R China

[7] Tianjin Med Univ, Dept Gastrointestinal Med Oncol, Canc Inst & Hosp, Tianjin 300060, Peoples R China

[8] Chinese Peoples Liberat Army, 301th Hosp, Dept Med Oncol, Beijing 100853, Peoples R China

[9] Jiangsu Prov Hosp, Dept Med Oncol, Nanjing 210029, Jiangsu, Peoples R China

[10] Fudan Univ, Dept Med Oncol, Zhongshan Hosp, Shanghai 200032, Peoples R China

[11] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing 100032, Peoples R China

[12] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Med Oncol, Wuhan 430030, Hubei, Peoples R China

[13] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Oncol, Sch Med, Shanghai 200035, Peoples R China

[14] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou 510060, Guangdong, Peoples R China

[15] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing 100021, Peoples R China

[16] Zhejiang Univ, Sch Med, Hosp 2, Dept Med Oncol, Hangzhou 310009, Zhejiang, Peoples R China

[17] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Peoples R China

[18] Nanjing Drum Tower Hosp, Dept Med Oncol, Nanjing 210008, Jiangsu, Peoples R China

[19] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510655, Peoples R China

来源：

CHINESE JOURNAL OF CANCER | 2016年 / 35卷

关键词：

Metastatic colorectal cancer; Maintenance therapy; Consensus; BEVACIZUMAB; CAPECITABINE; THERAPY; XELOX; CHEMOTHERAPY; OXALIPLATIN; STOP; GO;

D O I：

10.1186/s40880-015-0067-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The impact of maintenance therapy on progression-free survival and overall survival as well as quality of life of Chinese patients with metastatic colorectal cancer has long been under discussion. Recently, some phase III clinical trials have revealed that maintenance therapy can significantly prolong the progression-free survival while maintain an acceptable safety profile. Based on this evidence and common treatment practice in China, we now generated one Expert Consensus on Maintenance Treatment for Metastatic Colorectal Cancer in China to further specify the necessity of maintenance therapy, suitable candidates for such treatment, and appropriate regimens.

引用

页数：6

共 22 条

[1]

Arnold D, 2014, ASCO ANN M P

[2] Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment [J].

Bai, Long ;

Zhang, Dong-sheng ;

Wu, Wen-jing ;

Ren, Chao ;

Wang, De-shen ;

Wang, Feng ;

Qiu, Miao-zhen ;

Xu, Rui-hua .

MEDICAL ONCOLOGY, 2015, 32 (02)

[3] The incidences and mortalities of major cancers in China, 2010 [J].

Chen, Wan-Qing ;

Zheng, Rong-Shou ;

Zhang, Si-Wei ;

Zeng, Hong-Mel ;

Zou, Xiao-Nong .

CHINESE JOURNAL OF CANCER, 2014, 33 (08) :402-405

[4] Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study [J].

Chibaudel, Benoist ;

Maindrault-Goebel, Frederique ;

Lledo, Gerard ;

Mineur, Laurent ;

Andre, Thierry ;

Bennamoun, Mostepha ;

Mabro, May ;

Artru, Pascal ;

Carola, Elisabeth ;

Flesch, Michel ;

Dupuis, Olivier ;

Colin, Philippe ;

Larsen, Annette K. ;

Afchain, Pauline ;

Tournigand, Christophe ;

Louvet, Christophe ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5727-5733

[5] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study [J].

Diaz-Rubio, Eduardo ;

Gomez-Espana, Auxiliadora ;

Massuti, Bartomeu ;

Sastre, Javier ;

Abad, Albert ;

Valladares, Manuel ;

Rivera, Fernando ;

Safont, Maria J. ;

Martinez de Prado, Purificacion ;

Gallen, Manuel ;

Gonzalez, Encarnacion ;

Marcuello, Eugenio ;

Benavides, Manuel ;

Fernandez-Martos, Carlos ;

Losa, Ferran ;

Escudero, Pilar ;

Arrivi, Antonio ;

Cervantes, Andres ;

Duenas, Rosario ;

Lopez-Ladron, Amelia ;

Lacasta, Adelaida ;

Llanos, Marta ;

Tabernero, Jose M. ;

Anton, Antonio ;

Aranda, Enrique .

ONCOLOGIST, 2012, 17 (01) :15-25

[6]

Garcia Alfonso P, 2014, ANN ONCOL, V25, piv167, DOI DOI 10.1093/ANNONC/MDU333.3

[7]

Guan Zhong-Zhen, 2011, Chin J Cancer, V30, P682, DOI 10.5732/cjc.011.10188

[8]

Hagman H, 2014, ANN ONCOL, V25, piv175

[9] A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer [J].

Hecht, J. Randolph ;

Mitchell, Edith ;

Chidiac, Tarek ;

Scroggin, Carroll ;

Hagenstad, Christopher ;

Spigel, David ;

Marshall, John ;

Cohn, Allen ;

McCollum, David ;

Stella, Philip ;

Deeter, Robert ;

Shahin, Seta ;

Amado, Rafael G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :672-680

[10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

← 1 2 3 →